Besides, platelet-derived TGF-β could activate the TGF-β/Smad and NF-κB pathways, subsequently leading to the EMT in tumor cells (Labelle et al., 2011), which was suggested to significantly contribute to the development of chemoresistance (Fischer et al., 2015). This evidence concerns the gene TGFB1 and neoplasm.